22 October 2021

Physiomics plc

("Physiomics") or ("the Company")

Contract awards

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts by existing client Merck KGaA ("Merck") that it expects to be completed by the end of this calendar year.  These projects involve simulations of clinical efficacy of drug products in Merck's DNA damage/ repair portfolio.

Physiomics CEO, Dr Jim Millen, commented: "Merck remains a key, valued client and we are pleased to be continuing to work with them on a number of important development programs."

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.